Biologics Market to surpass US$ 456.83 billion by 2027 - Coherent Market Insights

Global Biologics Market, by Drug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others)), by Therapeutic Application (Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$  255.19 billion in 2019 and is expected to exhibit a CAGR of 7.6% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Key players in the market are involved in strategic collaborations with leading biopharmaceutical companies and research institutes for development of novel biopharmaceutical and biomedicines. Such strategic collaborations are expected to create conducive environment for growth of the global biologics market over the forecast period. For instance, in 2015, the University of Liverpool entered into a strategic collaboration with Medicines Patent Pool (MPP). Under the collaboration agreement, the University of Liverpool will license its patented Solid Drug Nanoparticle (SDN) technology, which can improve delivery of current HIV therapies into the body, to MPP.

Furthermore, in 2016, Biocon Ltd., a wholly owned subsidiary of Biocon SA entered into a collaboration with Laboratories PiSA S.A. de C.V, a Mexico-based company for co-development and commercialization of generic recombinant human insulin (rh-insulin) in the U.S. market

In 2017, AbCellera Biologics, Inc. entered into a collaboration with GlaxoSmithKline plc. for discovery of monoclonal antibodies against an undisclosed membrane protein target.

Browse 35 Market Data Tables and 49 Figures spread through 329 Pages and in-depth TOC on "Global Biologics Market, by Drug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme,  Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others)), by Therapeutic Application (Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"

To know the latest trends and insights related to global biologics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/biologics-market-2663

Key Takeaways of the Global Biologics Market:

• The global biologics market is expected to exhibit a CAGR of 7.6% over the forecast period (2019-2027), owing to increasing strategic collaborations by key players for biopharmaceutical and biomedicine drugs  
• Among drug class, monoclonal antibodies segment is expected to account for a major revenue share by 2027, owing to increasing regulatory approvals and launches of novel monoclonal antibodies for various indications. For instance, in February 2018, Novartis received the U.S Food and Drug Administration (FDA) approval for label update of its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor to treat moderate-to-severe plaque psoriasis.
• Major players operating in the global biologics market include Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.